2023 Was a tough 12 months for your biopharma field, with a number of corporations downsizing and restructuring their workforces to remain afloat. You'll find signs of recovery, as mergers and acquisitions picked up throughout the pharmaceutical and lifetime sciences field in the latter A part of 2023 and have https://sites.google.com/view/bio-sites/blog